Results 161 to 170 of about 20,944 (184)

Proximity-induced rewiring of oncogenic kinase triggers apoptosis

Merz ML, Shoba VM, Pergu R, Severance ZC, Munkanatta Godage DNP, Deb A, Kwok HS, Singh P, Singh S, Allen JB, Tian W, Gosavi PM, Chaudhary SK, Anokhina V, Weisberg EL, Payne NC, He Y, Dhaliwal R, Osadchey R, Shekhar M, Mazitschek R, Rees MG, Roth JA, Cui Q, Griffin JD, Liau BB, Choudhary A.   +26 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Characterization of a Monoclonal Antibody Specific for Novel Bcr/Abl Out-of-Frame Fusion Proteins

Hybridoma, 2011
The new tumor-specific antigens Bcr/Abl-OOF, identified in Philadelphia chromosome (Ph)-positive leukemia cells, are derived from an alternative splicing event involving BCR exons 1, 13, or 14 and ABL exons 4 and 5. The COOH-terminus of these transcription products contain an amino acid portion derived from an out-of-frame (OOF) reading of the ABL gene;
Casnici C, VOLPE, Gisella, Crotta K, PANUZZO, Cristina, Lattuada D, Cabras CA, Longhi R, SAGLIO, Giuseppe, Marelli O.   +8 more
openaire   +4 more sources

An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation

Leukemia Research, 2008
We have developed a simplified sandwich immunoassay to measure free circulating total and phosphorylated fusion BCR-ABL protein in patients with the t(9;22)(q34;q11) chromosomal translocation. The assay is based on immunoprecipitating BCR-ABL protein using beads coated with anti-BCR antibody and detecting the fusion protein with anti-ABL antibody and ...
Iman, Jilani, Hagop, Kantarjian, Homan, Faraji, Mercedes, Gorre, Jorge, Cortes, Oliver, Ottmann, Kapil, Bhalla, Susan, O'Brien, Francis, Giles, Maher, Albitar   +9 more
openaire   +2 more sources

Detection of BCR-ABL fusion proteins in patients with leukemia using a cytometric bead array

Leukemia & Lymphoma, 2011
Rapid and accurate detection of BCR-ABL fusion proteins is vital for the diagnosis and classification of leukemias, especially chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Recently, the cytometric bead array (CBA) system has been used to identify BCR-ABL proteins in leukemic cell lysates.
Wu, Yujie, Zhu, Yu, Qian, Sixuan, Wang, Li, Liu, Peng, Ge, Zeng, Zhang, Sujiang, Li, Jianyong   +7 more
openaire   +2 more sources

[Preparation and identification of rabbit polyclonal antibody against BCR-ABL b3a2 fusion protein].

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2021
Objective To prepare and identify rabbit anti-breakpoint cluster region-Abelson leukemia virus oncogene (BCR-ABL) b3a2 subtype polyclonal antibody. Methods A peptide containing the fusion sequence of the b3a2 subtype BCR-ABL fusion protein was designed and synthesized with the purity higher than 90%. The fusion polypeptide was coupled to Keyhole Limpet
Xiangning, Li, Jiayao, Qu, Jing, Jiang, Li, Wang, Dixian, Luo, Jia, Li, Lili, Duan, Rongzhang, He, Zheng, Hu   +8 more
openaire   +1 more source

Flow Cytometry Detection of BCR-ABL Fusion Proteins in Leukemia Patients- An Indian Experience.

Blood, 2009
Abstract Abstract 4710 Background The BCR-ABL fusion gene results from the translocation t(9;22). It is the hallmark of chronic myeloid leukemia (CML) and is present in a poor risk subgroup of precursor B cell Acute Lymphoblastic Leukemia(ALL),which represents 25 to 30% of adult ALL and
Soma Mukhopadhyay, Ujjal Kanti Roy, Ritwik Pandey, Pinaki Gupta, Jayasri Basak, Sanjay Sarkar, Ashis Mukhopadhyay, Haemato   +6 more
openaire   +1 more source

Targeting the Kinase Activity of the BCR-ABL Fusion Protein in Patients with Chronic Myeloid Leukemia

Current Molecular Medicine, 2005
Imatinib mesylate is a major advance in the therapy of patients with chronic myelogenous leukemia (CML). Imatinib mesylate binds to the inactive conformation of BCR-ABL tyrosine kinase suppressing the Philadelphia chromosome positive clone in CML. Clinical studies have yielded impressive results in all phases of CML.
Francis J, Giles, Jorge E, Cortes, Hagop M, Kantarjian   +2 more
openaire   +2 more sources

Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis

Leukemia, 2017
Two major types of leukemogenic BCR-ABL fusion proteins are p190BCR-ABLand p210BCR-ABL. Although the two fusion proteins are closely related, they can lead to different clinical outcomes. A thorough understanding of the signaling programs employed by these two fusion proteins is necessary to explain these clinical differences.
J A, Cutler, R, Tahir, S K, Sreenivasamurthy, C, Mitchell, S, Renuse, R S, Nirujogi, A H, Patil, M, Heydarian, X, Wong, X, Wu, T-C, Huang, M-S, Kim, K L, Reddy, A, Pandey   +13 more
openaire   +2 more sources

Immunologic Evaluation of Peptides Derived From BCR/ABL-Out-of-Frame Fusion Protein in HLA A2.1 Transgenic Mice

Journal of Immunotherapy, 2012
Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphocytic leukemia express, besides the main BCR/ABL transcripts, novel BCR/ABL transcripts derived from alternative splicing between BCR exons 1, 13, or 14 with ABL exons 4 and 5. Their translational products present at C-terminus an amino acid portion derived from out-of-frame (
Casnici C, VOLPE, Gisella, Crotta K, Lattuada D, SAGLIO, Giuseppe, Marelli O.   +5 more
openaire   +2 more sources